Aligos Therapeutics (ALGS) Scheduled to Post Earnings on Thursday

Aligos Therapeutics (NASDAQ:ALGS – Get Rating) is set to release its earnings data after the market closes on Thursday, March 9th. Analysts expect Aligos Therapeutics to post earnings of ($0.49) per share for the quarter.

Aligos Therapeutics Stock Performance

Shares of ALGS opened at $1.51 on Thursday. Aligos Therapeutics has a 52-week low of $0.84 and a 52-week high of $2.99. The stock has a 50 day simple moving average of $1.55 and a 200 day simple moving average of $1.26. The firm has a market capitalization of $64.66 million, a PE ratio of -0.57 and a beta of 2.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALGS. PDT Partners LLC acquired a new position in Aligos Therapeutics in the 1st quarter valued at $57,000. AQR Capital Management LLC acquired a new position in Aligos Therapeutics in the 2nd quarter valued at $58,000. Prelude Capital Management LLC acquired a new position in Aligos Therapeutics in the 1st quarter valued at $58,000. Mirabella Financial Services LLP acquired a new position in Aligos Therapeutics in the 1st quarter valued at $88,000. Finally, XTX Topco Ltd acquired a new position in Aligos Therapeutics in the 1st quarter valued at $94,000. 64.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Jefferies Financial Group raised Aligos Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the stock from $2.50 to $3.00 in a research report on Friday, January 6th. Piper Sandler increased their price target on Aligos Therapeutics from $3.00 to $7.00 in a research note on Monday, January 16th. Finally, SVB Leerink dropped their price target on Aligos Therapeutics from $3.00 to $2.00 and set a “market perform” rating on the stock in a research note on Thursday, November 3rd.

About Aligos Therapeutics

(Get Rating)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.